CJC 1295 Ipamorelin Explained: Science, Studies & What to Know

Disclosure: This article discusses research compounds without FDA approval for therapeutic use. Nothing here is medical advice. Research chemicals are not for human consumption.

No published or registered trial has tested CJC-1295 and ipamorelin together in people. The numbers quoted for the pair come from CJC-1295 alone, and the one ipamorelin trial with published efficacy results didn’t beat placebo.

This page covers what each peptide has been tested on and what the stacking idea rests on. It also covers the risks and what’s in the vial.

Choosing between ipamorelin and a GHRH analog like sermorelin? Our ipamorelin vs sermorelin guide lays out the differences.

Quick takeaways

What each peptide is

CJC-1295 is a GHRH analog, a tetrasubstituted form of human GHRH(1-29) (3). It comes in two forms. The DAC version has an extra tail that bonds to albumin in your blood, and its half-life in people is 5.8 to 8.1 days (1). The no-DAC version lacks that tail, and no published human trial reports its half-life. See our CJC-1295 without DAC guide.

Ipamorelin is a five-amino-acid peptide that releases growth hormone through a GHRP-like receptor, so it’s often called a ghrelin mimetic (4, 6). In healthy men, an IV dose produced a single GH pulse that peaked at about 40 minutes. Its half-life was about 2 hours (5).

Why people stack them

GHRH and the GHRPs act on different receptors. In 1990, Bowers and colleagues gave 18 men a GHRP (GHRP-6) with GHRH and found the GH release was synergistic at submaximal GHRP doses (8). A 1996 study saw the same with hexarelin in 7 healthy men, and an additive effect in 10 men with type 1 diabetes (9).

Those were single IV doses that measured GH, with older peptides. Nobody has run the test with ipamorelin and CJC-1295. And a bigger GH spike isn’t an outcome.

What the human data show

CJC-1295 with DAC has two randomized, placebo-controlled trials in healthy adults aged 21 to 61. After one injection, GH rose 2 to 10 times for six days or more, and IGF-1 rose 1.5 to 3 times for 9 to 11 days. The trials measured hormone levels and safety, and reported no serious adverse reactions (1). A second study found GH pulses stayed intact a week after one injection, while the lowest levels between pulses rose 7.5 times (2).

Ipamorelin has one published efficacy trial. It randomized 117 adults after bowel surgery to IV ipamorelin or placebo. Median time to the first tolerated meal was 25.3 hours on ipamorelin and 32.6 on placebo (p=0.15). It was well tolerated (6). A second Phase 2 trial in 320 patients is registered as completed, with no results posted (7).

No published trial has measured body composition, sleep or recovery with either peptide.

The closest long trial uses a different molecule. In 2008, 65 healthy adults aged 60 to 81 took an oral ghrelin mimetic, MK-677, or placebo in a two-year modified-crossover trial. At 12 months, GH and IGF-1 had risen to young-adult levels, and fat-free mass had risen 1.1 kg against a 0.5 kg loss on placebo. Strength and function didn’t change. Body weight rose 2.7 kg against 0.8 kg, fasting glucose rose and insulin sensitivity fell (10).

Risks

FDA lists CJC-1295 among withdrawn bulk-drug nominations and says it has identified serious adverse events, including increased heart rate. It lists ipamorelin in Category 2 for 503B facilities, and in the withdrawn table, citing a published report of serious adverse events including death with intravenous use (13).

In 2006, ConjuChem halted a Phase 2 trial of CJC-1295 in HIV patients after a participant died. The company later reported that the attending physician judged undiagnosed coronary artery disease the most likely cause, according to secondary accounts of its findings (24). The registry lists the trial as terminated (12).

GH raises IGF-1. In the UK Biobank, each 5 nmol/L higher IGF-1 carried a hazard ratio of 1.18 for thyroid cancer, 1.11 for breast, 1.08 for prostate and 1.08 for colorectal. That’s observational data, and the authors say reverse causality can’t be excluded (11).

A 2026 review lists prolactin and cortisol elevations, appetite changes, dysglycemia, fluid retention, muscle and joint pain and injection-site reactions among the reported effects of these peptides. It notes the uncertainty around composition, dose and stacking in unregulated supply (17). A 2026 Sports Medicine review says rigorous human safety data are scarce (23).

Legal and anti-doping status

Neither peptide is an FDA-approved drug. HHS announced an interim enforcement-discretion policy for compounding on 28 October 2026. It covers six peptides, and CJC-1295 and ipamorelin aren’t among them (14). WADA prohibits CJC-1295 as a GHRH analogue and ipamorelin as a growth hormone secretagogue, both under S2 (15).

The GHRH analog FDA currently approves is tesamorelin, a prescription drug for abdominal fat in HIV-associated lipodystrophy (19).

What’s in the vial

Quality is the open question. Doping labs found Gly-ipamorelin, ipamorelin with an extra glycine at the front, in black-market growth products (16). JBJS Reviews cites product-quality concerns for CJC-1295 and ipamorelin (18). In a Belgian screening of ten falsified peptide drugs bought from suspected illegal internet pharmacies, purity ranged from 5% to 75% for cysteine-containing peptides, and some samples held arsenic and lead (20).

Check whether the label says DAC or no DAC. The human CJC-1295 trials used the DAC form. A certificate of analysis shows what one lot contained. See how to verify a peptide COA, and compare sellers in the best peptide vendors guide.

For related reading, see our CJC-1295 without DAC guide and guide to ipamorelin for women.

Frequently Asked Questions

References

1. Teichman SL et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006;91(12):4792-7. doi:10.1210/jc.2006-1702
3. Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. doi:10.1210/en.2004-1286
4. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. doi:10.1530/eje.0.1390552
5. Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6. doi:10.1023/a:1018955126402
6. Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. doi:10.1007/s00384-014-2030-8
7. ClinicalTrials.gov NCT01280344. Phase II dose-finding study of ipamorelin for recovery of gastrointestinal function after bowel resection (Helsinn; completed, no results posted)
8. Bowers CY et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. doi:10.1210/jcem-70-4-975
9. Giustina A et al. Hypothalamic control of growth hormone (GH) secretion in type I diabetic men: effect of the combined administration of GH-releasing hormone and hexarelin. Endocr Res. 1996;22(2):159-74. doi:10.1080/07435809609030505
10. Nass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-11. doi:10.7326/0003-4819-149-9-200811040-00003
11. Knuppel A et al. Circulating insulin-like growth factor-I concentrations and risk of 30 cancers: prospective analyses in UK Biobank. Cancer Res. 2020;80(18):4014-21. doi:10.1158/0008-5472.CAN-20-1281
12. ClinicalTrials.gov NCT00267527. A study to evaluate CJC 1295 in HIV patients with visceral obesity (ConjuChem; terminated) and aidsmap. Lipodystrophy study halted after patient death. July 2006
13. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks
14. Drug Topics. HHS lets pharmacies compound peptides as FDA writes official rule. 29 October 2026
15. WADA 2026 Prohibited List, section S2, as reproduced by DSHS Cologne.
16. Krug O et al. Analysis of new growth promoting black market products. Growth Horm IGF Res. 2018;41:1-6. doi:10.1016/j.ghir.2018.05.001
17. Dominikowski A et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. 2026;17:1822475. doi:10.3389/fendo.2026.1822475
18. Villegas Meza AD et al. Injectable peptides in sports medicine: a structured narrative review of evidence, safety, and antidoping implications. JBJS Rev. 2026;14(5). doi:10.2106/JBJS.RVW.26.00027
19. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-91. doi:10.2165/11202240-000000000-00000
20. Janvier S et al. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018;188:795-807. doi:10.1016/j.talanta.2018.06.023
21. Bowers CY. GH releasing peptides: structure and kinetics. J Pediatr Endocrinol. 1993;6(1):21-31. doi:10.1515/jpem.1993.6.1.21
22. Hansen BS et al. Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999;141(2):180-9. doi:10.1530/eje.0.1410180
23. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921-35. doi:10.1007/s40279-026-02437-0
24. FDAnews. ConjuChem reveals findings of patient death investigation. August 2006.